Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;34(6):1008-1009.
doi: 10.1038/s41433-019-0745-z. Epub 2019 Dec 16.

Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

Ashish Sharma  1 , M Hafeez Faridi  2 , Nilesh Kumar  3 , Nikulaa Parachuri  3 , Rohini Sharma  4 , Baruch D Kuppermann  5 , Francesco Bandello  6 , Anat Loewenstein  7 , Carl D Regillo  8
Affiliations

Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

Ashish Sharma et al. Eye (Lond). 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ashish Sharma CONSULTANT: Novartis India, Allergan Global, Intas India, Bayer India. M Hafeez Faridi: None. Nilesh Kumar: None. Nikulaa Parachuri: None. Rohini Sharma: None. BD Kuppermann CLINICAL RESEARCH: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; CONSULTANT: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. Francesco Bandello CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. Anat Loewenstein CONSULTANT: Allergan, Novartis, Roche, Notal Vision, Fiorsightslabs, Beyeonics, Bayer Health Care. Carl D Regillo: None.

References

    1. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol. 2018;12:2137–43. doi: 10.2147/OPTH.S180393. - DOI - PMC - PubMed
    1. Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Ther Adv Gastroenterol. 2019;12:1756284819842748. doi: 10.1177/1756284819842748. - DOI - PMC - PubMed
    1. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–16. doi: 10.1016/S0140-6736(17)30068-5. - DOI - PubMed
    1. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study. Ophthalmologica. 2019;241:24–31. doi: 10.1159/000488602. - DOI - PMC - PubMed
    1. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br. J. Ophthalmol. (2019). - PubMed